Secukinumab versus standard-of-care in axial spondyloarthritis - report from EULAR2024

from Medical Digest & Congress Report · host Medical Congress News

Professor Denis Poddubnyy shared the results of AScalate trial, Secukinumab versus standard-of-care in axial spondyloarthritis, a randomized controlled open-label trial for treat-to-target outcomes. Video: https://medicaldigest.org/scientific-contents/interview:secukinumab-versus-standard-care-axial-spondyloarthritis

Episode metadata supplied by the publisher feed · Published Jun 20, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Secukinumab versus standard-of-care in axial spondyloarthritis - report from EULAR2024

0:00 6:32

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 6 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on June 20, 2024.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!